摘要
目的:探讨甘麦大枣汤联合5-羟色胺再摄取抑制剂(SSRIs)治疗抑郁症的临床效果。方法:选取2017年3月-2018年3月在十堰市中西医结合医院就诊的抑郁症患者共78例,使用随机表法将其分成两组,每组各39例。对照组单用一种SSRIs治疗,观察组在此基础上联用甘麦大枣汤治疗。对比两组治疗前后汉密尔顿抑郁量表(HAMD-17)评分、两组SSRIs使用强度评定。结果:两组患者抑郁症状评分显著低于治疗前,差异有统计学意义(P<0.05);治疗6周后,观察组患者的HAMD评分显著比对照组要低,差异有统计学意义(P<0.05);观察组患者SSRI平均使用强度显著比对照组要低,差异有统计学意义(P<0.05)。结论:甘麦大枣汤联合SSRIs抗抑郁治疗具有配伍优势并可降低SSRIs的剂量。
Objective:To investigate the clinical efficacy of Ganmai Dazao Decoction combined with selective serotonin reuptake inhibitors(SSRIs)in the treatment of depression.Methods:A total of 78 patients with depression,who were treated in Shiyan Hospital of Integrated Traditional Chinese and Western Medicine from March 2017 to March 2018,were enrolled in this study.They were randomly divided into two groups,with 39 cases in each group.The control group was treated with SSRIs alone and the observation group was treated with Ganmai Dazao Decoction combined with SSRIs.The Hamilton Depression Scale(HAMD-17)scores before and after treatment and the intensity of SSRIs were compared between the two groups.Results:After treatment,the HAMD scores of the two groups were significantly lower than those before treatment,with statistically significant difference(P<0.05).After 6 weeks of treatment,the HAMD scores of the observation group were significantly lower than those of the control group,with statistically significant difference(P<0.05).The average SSRI intensity of the observation group was significantly lower than that of the control group,and the difference was statistically significant(P<0.05).Conclusion:Ganmai Dazao Decoction combined with SSRIs for antidepressant therapy has the advantages of compatibility and can reduce the dosage of SSRIs.
作者
成加林
牛军涛
陈财德
何杰
周碧海
许晴丽
Cheng Jia-lin;Niu Jun-tao;Chen Cai-de;He Jie;Zhou Bi-hai;Xu Qing-li(Department of Psychiatry,Shiyan Hospital of Integrated Traditional Chinese and Western Medicine,Shiyan 442000,Hubei Province,China)
出处
《中国社区医师》
2022年第14期70-72,共3页
Chinese Community Doctors
关键词
甘麦大枣汤
抑郁症
5-羟色胺再摄取抑制剂
Ganmai Dazao Decoction
Depression
Selective serotonin reuptake inhibitors